title: Role of Ranolazine in cardiovascular disease and diabetes: Exploring beyond angina.
abstract: Ranolazine was FDA approved for chronic angina in 2006. Since then, there has been extensive research involving this drug. The mechanism of action, debatable at the time of approval, has been demonstrated. Ranolazine acts via inhibition of late sodium channel current in the myocardium. This acts by lowering abnormally high cytosolic calcium levels. Other possible clinical applications of Ranolazine have also been explored. Out of many lines of investigation, its effects in atrial fibrillation, especially post-CABG and recurrent atrial fibrillation show promise. It has also shown definite HbA1c lowering effects when used in diabetics with coronary artery disease. Other possible indications for the drug include pulmonary arterial hypertension, diastolic dysfunction and chemotherapy-induced cardiotoxicity. This review aims to summarize major research regarding Ranolazine in potential applications beyond chronic angina. There are few dedicated large, randomized, phase III trials exploring the newer effects of Ranolazine. There are a few such trials underway, but more are needed.
authors.affiliation: Cleveland Clinic, Cleveland, OH, USA.
authors.forename: Kinjal
authors.initials: K
authors.lastname: Banerjee
authors.affiliation: Department of Internal Medicine, St. Vincent Charity Medical Center, A Teaching Affiliate of Case Western Reserve University, Cleveland, OH, USA. Electronic address: raktimghoshmd@gmail.com.
authors.forename: Raktim Kumar
authors.initials: RK
authors.lastname: Ghosh
authors.affiliation: Department of Internal Medicine, St. Vincent Charity Medical Center, A Teaching Affiliate of Case Western Reserve University, Cleveland, OH, USA.
authors.forename: Sravani
authors.initials: S
authors.lastname: Kamatam
authors.affiliation: IPGMER, Kolkata, India.
authors.forename: Arnab
authors.initials: A
authors.lastname: Banerjee
authors.affiliation: Department of Cardiovascular Medicine, St. Vincent Charity Medical Center, A Teaching Affiliate of Case Western Reserve University, Cleveland, OH, USA.
authors.forename: Anjan
authors.initials: A
authors.lastname: Gupta
mesh_terms: D000368:Aged; D000787:Angina Pectoris / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000401:mortality / Q000517:prevention & control; D002318:Cardiovascular Diseases / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality; D002908:Chronic Disease; D003920:Diabetes Mellitus / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D000069458:Ranolazine / Q000627:therapeutic use*; D018570:Risk Assessment; D012380:Role; D026941:Sodium Channel Blockers / Q000627:therapeutic use*; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D026941:Sodium Channel Blockers; D000069458:Ranolazine
keywords: Angina; Atrial fibrillation; Diabetes; Diastolic dysfunction; Pulmonary arterial hypertension; Ranolazine